Literature DB >> 3663481

Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study.

M P Coleman1, C M Bell, P Fraser.   

Abstract

The risk of second primary malignancy was assessed in a population-based cohort study of all persons registered with Hodgkin's disease (n = 2,970), ovarian cancer (n = 11,802) and testicular cancer (n = 2,013) in the South Thames Cancer Registry during the period 1961-80, to identify for further study those second malignancies which might be treatment-related. A total of 244 second malignancies was observed. After adjustment for age, sex and calendar period, the relative risk of any second malignancy was 1.4 (90% confidence interval (CI) 1.1-1.7) after Hodgkin's disease, 1.1 (90% CI 1.0-1.2) after ovarian cancer and 0.7 (90% CI 0.5-1.0) after testicular cancer. In particular, the relative risk for leukaemia was 11.9 after Hodgkin's disease, 3.7 after ovarian cancer and 2.5 after testicular cancer. Excess risks were also observed for cancers of the cervix and lung after Hodgkin's disease, for cancers of the breast, lung and rectum after ovarian cancer, and for contralateral testicular cancer. Confounding by social class or smoking does not explain these observations. The excess risks of leukaemia and of second cancer were higher in patients first diagnosed with Hodgkin's disease and ovarian cancer in the 1970s than for those first diagnosed in the 1960s. Increased use of multiple-agent chemotherapy regimes for these tumours in the 1970s may have contributed to these increases in excess risk.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663481      PMCID: PMC2002200          DOI: 10.1038/bjc.1987.201

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Acute leukemia after alkylating-agent therapy of ovarian cancer.

Authors:  R R Reimer; R Hoover; J F Fraumeni; R C Young
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

Review 2.  Multiple primary cancers in Hodgkin's disease.

Authors:  R S Brody; D Schottenfeld
Journal:  Semin Oncol       Date:  1980-06       Impact factor: 4.929

3.  Acute myeloid leukemia following treatment of Hodgkin's disease: a review.

Authors:  H W Grünwald; F Rosner
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

Review 4.  Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases.

Authors:  H W Grünwald; F Rosner
Journal:  Arch Intern Med       Date:  1979-04

5.  The analysis of mortality by the subject-years method.

Authors:  G Berry
Journal:  Biometrics       Date:  1983-03       Impact factor: 2.571

6.  Further advances in the management of malignant teratomas of the testis and other sites.

Authors:  E S Newlands; R H Begent; G J Rustin; D Parker; K D Bagshawe
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

7.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; A G Sheil; J Peto; R Doll
Journal:  Br Med J       Date:  1979-12-08

8.  Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).

Authors:  J D Boice; M H Greene; J Y Killen; S S Ellenberg; R J Keehn; E McFadden; T T Chen; J F Fraumeni
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

9.  Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.

Authors:  M H Greene; J D Boice; B E Greer; J A Blessing; A J Dembo
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

10.  Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.

Authors:  J M Kaldor; N E Day; P Band; N W Choi; E A Clarke; M P Coleman; M Hakama; M Koch; F Langmark; F E Neal
Journal:  Int J Cancer       Date:  1987-05-15       Impact factor: 7.396

View more
  11 in total

Review 1.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Renal cell carcinoma following testicular cancer: case report and literature review.

Authors:  Nathan Lawrentschuk; Dennis Gyomber; Damien M Bolton
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 3.  Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Mubarak M Al-Mansour; Turki M Al-Fayea; Meteb Al-Foheidi; Ali M Bayer; Osama A Elmasri
Journal:  Lung       Date:  2012-10-06       Impact factor: 2.584

4.  Primary squamous cell carcinoma of the breast after cured Hodgkin's disease.

Authors:  K Kuroi; A Osaki; H Yamada; M Toi; T Toge; Y Takimoto; A Kuramoto; K Arihiro; K Inai
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Khaled M Abouelkhair; Ghieth A Kazkaz; Osama A Elmasri; Meteb Al-Foheidi
Journal:  BMC Cancer       Date:  2012-05-28       Impact factor: 4.430

6.  Subsequent primary cancers in relation to treatment of ovarian cancer.

Authors:  P Prior; D J Pope
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

Review 7.  Temporal trends in the risk of developing multiple primary cancers: a systematic review.

Authors:  Yuanzi Ye; Amanda L Neil; Karen E Wills; Alison J Venn
Journal:  BMC Cancer       Date:  2016-11-04       Impact factor: 4.430

8.  Hodgkin's disease: subsequent primary cancers in relation to treatment.

Authors:  P Prior; D J Pope
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

9.  Should cancer survivors fear radiation-induced sarcomas?

Authors:  M Feigen
Journal:  Sarcoma       Date:  1997

10.  Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.

Authors:  Yi-Ping Hung; Chia-Jen Liu; Yu-Wen Hu; Min-Huang Chen; Chun-Pin Li; Chiu-Mei Yeh; Tzeon-Jye Chiou; Tzeng-Ji Chen; Muh-Hwa Yang; Yee Chao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.